Discontinued — last reported Q3 '22

Current Liabilities

Expected Restructuring and Related Costs

Analysis

StatementBalance Sheet Statement
SectionCurrent Liabilities
First reportedQ2 2022
Last reportedQ3 2022
Metric ID: restructuring_costs_expected

Business Segments

View all
SegmentQ1 '26
Biopharma$3.70B
Total—